These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 36760507)

  • 21. A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients.
    Li PY; Li SQ; Gao SG; Dong DY
    Med Hypotheses; 2022 Feb; 159():110754. PubMed ID: 35002020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous CRISPR-Cas System-Based Genome Editing and Antimicrobials: Review and Prospects.
    Li Y; Peng N
    Front Microbiol; 2019; 10():2471. PubMed ID: 31708910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Cas13-Mediated Knockdown of Regulator of G-Protein Signaling 8 (RGS8) Does Not Affect Purkinje Cell Dendritic Development.
    Wu QW; Kapfhammer JP
    Front Cell Dev Biol; 2022; 10():854273. PubMed ID: 35712654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA-targeting strategies as a platform for ocular gene therapy.
    Kumar S; Fry LE; Wang JH; Martin KR; Hewitt AW; Chen FK; Liu GS
    Prog Retin Eye Res; 2023 Jan; 92():101110. PubMed ID: 35840489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmable RNA base editing with photoactivatable CRISPR-Cas13.
    Yu J; Shin J; Yu J; Kim J; Yu D; Heo WD
    Nat Commun; 2024 Jan; 15(1):673. PubMed ID: 38253589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The double life of CRISPR-Cas13.
    Bot JF; van der Oost J; Geijsen N
    Curr Opin Biotechnol; 2022 Dec; 78():102789. PubMed ID: 36115160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and application of sensitive, specific, and rapid CRISPR-Cas13-based diagnosis.
    Shihong Gao D; Zhu X; Lu B
    J Med Virol; 2021 Jul; 93(7):4198-4204. PubMed ID: 33599292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unleashing the potential: type I CRISPR-Cas systems in actinomycetes for genome editing.
    Wang S; Zeng X; Jiang Y; Wang W; Bai L; Lu Y; Zhang L; Tan GY
    Nat Prod Rep; 2024 Sep; 41(9):1441-1455. PubMed ID: 38888887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy.
    Elliott EK; Haupt LM; Griffiths LR
    Transgenic Res; 2021 Apr; 30(2):129-141. PubMed ID: 33609253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications.
    Tang T; Han Y; Wang Y; Huang H; Qian P
    Front Cell Dev Biol; 2021; 9():677587. PubMed ID: 34386490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of CRISPR/Cas System for Improving Genome Editing Efficiency in
    Zhao Y; Wang F; Wang C; Zhang X; Jiang C; Ding F; Shen L; Zhang Q
    Front Microbiol; 2020; 11():625862. PubMed ID: 33488567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics.
    Xue Y; Chen Z; Zhang W; Zhang J
    Bioengineering (Basel); 2022 Jun; 9(7):. PubMed ID: 35877342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Versatile Type V CRISPR Effectors and Their Application Prospects.
    Tong B; Dong H; Cui Y; Jiang P; Jin Z; Zhang D
    Front Cell Dev Biol; 2020; 8():622103. PubMed ID: 33614630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research advances in photoactivatable CRISPR gene editing technology].
    Zhao J; Cao S; Zhang Y; Guo Y; Li B; Ma J; Ma X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 Sep; 39(9):1025-1029. PubMed ID: 36082579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA editing with CRISPR-Cas13.
    Cox DBT; Gootenberg JS; Abudayyeh OO; Franklin B; Kellner MJ; Joung J; Zhang F
    Science; 2017 Nov; 358(6366):1019-1027. PubMed ID: 29070703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation.
    Mahas A; Neal Stewart C; Mahfouz MM
    Biotechnol Adv; 2018; 36(1):295-310. PubMed ID: 29197619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overview of applications of CRISPR-Cas technologies in biomedical engineering.
    Jamehdor S; Zaboli KA; Naserian S; Thekkiniath J; Omidy HA; Teimoori A; Johari B; Taromchi AH; Sasano Y; Kaboli S
    Folia Histochem Cytobiol; 2020; 58(3):163-173. PubMed ID: 32978771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR-Cas13 Precision Transcriptome Engineering in Cancer.
    Granados-Riveron JT; Aquino-Jarquin G
    Cancer Res; 2018 Aug; 78(15):4107-4113. PubMed ID: 30021724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA-Targeting CRISPR-Cas Systems and Their Applications.
    Burmistrz M; Krakowski K; Krawczyk-Balska A
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.